MedTrace Logo

Effects Of Turkish Coffee Consumption On Cardiovascular Markers And Sleep In Healthy Women

NCT07133373 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-08-21

No results posted yet for this study

Summary

This randomized controlled trial aims to evaluate the short-term effects of daily unfiltered Turkish coffee consumption on cardiovascular parameters, appetite-regulating hormones, glucose metabolism, inflammatory markers, and sleep quality in healthy young women. Forty participants will be randomly assigned to an intervention group, consuming standardized servings of Turkish coffee for four weeks, or to a control group abstaining from coffee during the same period. Measurements will be taken at baseline and after the intervention, including blood pressure, lipid profile, leptin, ghrelin, glucose metabolism markers, inflammatory biomarkers, body composition, and sleep quality indices.

Conditions

  • Effects of Turkish Coffee Consumption on Cardiovascular Markers and Sleep in Healthy Women
  • Cardiometabolic Health Markers, Appetite-regulating Hormones, Inflammation, and Sleep Quality in Healthy Women

Interventions

OTHER

Turkish Coffee (unfiltered, boiled)

Standardized Turkish coffee (unfiltered and boiled) was administered once daily for 4 weeks. Each serving was approximately 75 mL, prepared using a consistent protocol without added sugar or milk. The coffee was sourced from the same batch and brewed in a traditional cezve. Compliance and adverse effects were monitored throughout the intervention.

Sponsors & Collaborators

  • University of Petra

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2024-10-30
Completion
2024-10-30

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07133373 on ClinicalTrials.gov